Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 6/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.45 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17619613 | 0.83 | SMN1; SMN2 (0.44) | MAPK1KDM4ELMNAPOLBTRPA1 | |
| SCHEMBL17619939 | 0.80 | MEN1 (0.47) | MAPK1KDM4ELMNAPOLBTP53 | |
| SCHEMBL17609632 | 0.80 | TRPA1 (0.72) | TRPA1TP53RXFP1 | |
| SCHEMBL10130856 | 0.78 | TRPA1 (0.54) | MAPK1KDM4ELMNAPOLBTRPA1 | |
| SCHEMBL17609719 | 0.78 | TRPA1 (0.66) | TRPA1 | |
| SCHEMBL15384326 | 0.78 | CYP1A2 (0.49) | MAPK1KDM4ELMNAPOLBCYP1A2 | |
| SCHEMBL1065288 | 0.78 | TRPA1 (0.71) | MAPK1KDM4ELMNAPOLBTRPA1 | |
| SCHEMBL21861546 | 0.77 | KMT2A (0.67) | MAPK1KDM4ELMNAPOLBTRPA1 | |
| SCHEMBL17609885 | 0.77 | TRPA1 (0.73) | TRPA1 | |
| SCHEMBL15384477 | 0.77 | CYP1A2 (0.50) | MAPK1KDM4ELMNAPOLBTRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3193880-B1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | LILLY CO ELI (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3193880-B1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | LILLY CO ELI (US) | 2020-03-25 | — | — | EP | disclosed |
| US-10519158-B2 | Inhibiting the transient receptor potential A1 ion channel | ELI LILLY AND COMPANY (US) | 2019-12-31 | — | — | US | disclosed |
| US-10519158-B2 | Inhibiting the transient receptor potential A1 ion channel | ELI LILLY AND COMPANY (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190330212-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | ELI LILLY AND COMPANY | 2019-10-31 | — | — | US | disclosed |
| US-10221177-B2 | Inhibiting the transient receptor potential A1 ion channel | HYDRA BIOSCIENCES, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170275285-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | ELI LILLY AND COMPANY | 2017-09-28 | — | — | US | disclosed |
| US-20170275285-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | ELI LILLY AND COMPANY | 2017-09-28 | — | — | US | disclosed |
| US-20170275285-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | ELI LILLY AND COMPANY | 2017-09-28 | — | — | US | disclosed |
| EP-3193880-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | Hydra Biosciences, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016044792-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | HYDRA BIOSCIENCES, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016044792-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | HYDRA BIOSCIENCES, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10519158-B2 | Inhibiting the transient receptor potential A1 ion channel | TRPV1, TRPA1, TRPV2 | MAPK1 1383/4885KDM4E 4811/4885LMNA 2566/4885 |
| US-10221177-B2 | Inhibiting the transient receptor potential A1 ion channel | TRPV1, TRPA1, TRPV2 | MAPK1 1383/4885KDM4E 4811/4885LMNA 2566/4885 |
| US-20170275285-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | TRPV1, TRPA1, TRPV2 | MAPK1 1383/4885KDM4E 4811/4885LMNA 2566/4885 |
| US-20190330212-A1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | TRPV1, TRPA1, TRPV2 | MAPK1 1383/4885KDM4E 4811/4885LMNA 2566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.